ACE-Inhibitors and ARBs during COVID-19

Today’s pearl is about the use of ACE-Is and ARBs in patients with COVID-19

Should they be continued?

 Many are wondering if they should continue taking their angiotensin converting enzyme inhibitors (ACE-I) (eg, lisinopril) or angiotensin receptor blockers (ARB) (eg, losartan) for hypertension, heart failure, etc. during the COVID-19 pandemic.

The answer is YES! (Patel 2020)

As with all drug therapies being studied amid this pandemic, recommendations could change. There is ongoing research assessing the role of ACE2 in SARS-CoV-2 and whether ACE-Is or ARBs have an effect on outcomes.

The American Heart Association currently recommends continuing ACE-I or ARB therapy during COVID-19 (HFSA/ACC/AHA statement). If patients have concerns, they should talk to their prescriber before discontinuing.




Author: Bryan D. Hayes, PharmD

Attending Pharmacist, Emergency Medicine and Toxicology, Massachusetts General Hospital; Assistant Professor of EM, Harvard Medical School

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s